Bis zu 90% sparen! Kostenloser Depotgebühren-Check
030-275 77 6400
DAX-0,17 % EUR/USD+0,42 % Gold-0,13 % Öl (Brent)-1,19 %

Ich komme ... - 500 Beiträge pro Seite

Beitrag schreiben

Begriffe und/oder Benutzer


hmm,wenn du wegen soner kleingkeit schon kommst,weisste aber nicht was gut ist :D

tb 2
@ tb 2

Erzähl mir mal was besser ist, vielleicht kann ich ja noch was lernen.

adsx zb :D.bei LYNX kannst du doch keine grossen gewinne haben bei dem chart.
tb 2
sieht so aus als könntest du wirklich was von mir lernen ;):D
nichts für ungut
tb 2 nur 5 Tagen verdoppelt!

@thebull 2
hasde adsx denn auch?

gruß codex

einige comments aus übersee:

A.But why???? I`m unable to locate any meaningful news except the expansion of Shares Outstanding by 90 million. Admittedly, that could be perceived as a vote of confidence. Alternatively, the board/executives are simply creating a lot of hype about the Verichip, only to cash out at the peak.
Has any substantive info been released? For instance have they signed any contracts with municipal dog pounds, the Dept. of Justice, the DoD, or psychotically concerned parents that want to track their childrens` every move via GPS????

Could today`s movement might just be more of the same momentum?

B.i agree. i`m baffled on the move on no news. of course we could see news soon and it will sell off like crazy. buy on the rumor, sell on the news...

@ [KERN]Codex
was ich hab ist doch egal.
Aeppler hat gefragt was besser ist und ich hab geantwortet.
wie man sieht hatte ich recht :D
tb 2

bei dem move kann man nicht meckern.

Aber der Chart sieht ja ähnlich aus wie bei lynx,
nur dass lynx das schönste noch vor sich hat.

wenn ich gewusst hätte, das adsx so läuft, hätte ich vorher gekauft.

sollte natürlich adsx heißen (applied digital solut.)

Applied Digital Solutions (ADSX: news, chart, profile) leapt more than 24 percent in midday action. Before the opening bell, Digital Angel Corp. (DOC: news, chart, profile), which is 82-percent owned by Applied Digital, announced that it has signed a 10-year agreement to provide its food safety and export assurance technology for the Brazilian government`s national lifestock identification project. Financial terms of the deal weren`t disclosed. Digital Angel shares leapt more than 20 percent.

gruß codex…
hier mal news zu deiner lynx

ynx Arranges $22.6 Million in Private Equity Financing
Alle Nachrichten

17.04. / 23:43

< zurück <

> Archiv >

Lynx Therapeutics, Inc. announced today it has obtained commitments to purchase common stock and warrants for
common stock worth up to approximately $22.6 million. The financing includes the sale of 14.6 million newly issued
shares of common stock at $1.55 per share and the issuance of warrants to purchase approximately 5.8 million
shares of common stock at an exercise price of $1.94 per share. The transaction is expected to be consummated
by the end of the month.

Friedman, Billings, Ramsey & Co., Inc. acted as sole manager for the transaction. Lynx has agreed to file with the
U.S. Securities and Exchange Commission a resale registration statement relating to the common stock to be
issued in the transaction.

Lynx expects to use the net proceeds from the financing to support ongoing commercial, business development
and research and development activities. Lynx``s efforts will also be directed toward the expansion of the
commercial applications of its genomics technologies-principally Massively Parallel Signature Sequencing, or
MPSS(TM), which provides comprehensive and quantitative digital gene expression data important to modern
systems biology research-and the continued development of its Protein ProFiler(TM) proteomics technology.

Lynx is a leader in the development and application of novel technologies for the discovery of gene expression
patterns important to the pharmaceutical, biotechnology and agricultural industries. These technologies are based
on the Megaclone(TM) technology, Lynx``s unique and proprietary cloning procedure, which transforms a sample
containing millions of DNA molecules into one made up of millions of micro-beads, each of which carries
approximately 100,000 copies of one of the DNA molecules in the sample. Megaclone(TM) technology and
MPSS(TM) together provide comprehensive and quantitative digital gene expression data. Lynx is also developing a
proteomics technology, Protein ProFiler(TM), which is expected to provide high-resolution analysis of complex
mixtures of proteins from cells or tissues. For more information, visit Lynx``s web site at

This press release contains "forward-looking" statements, including statements related to the intended use of the
proceeds from this financing, the expansion of Lynx``s commercial applications of its technologies, future revenues
and the potential success of commercialization efforts. Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking statements. Words such as "believes,"
"anticipates," "plans," "predicts," "expects," "estimates," "intends," "will," "continue," "may," "potential," "should,"
"confident" and similar expressions are intended to identify forward-looking statements. There are a number of
important factors that could cause the results of Lynx to differ materially from those indicated by these
forward-looking statements, including, among others, risks detailed from time to time in the Lynx``s SEC reports,
including its Annual Report on Form 10-K for the year ended December 31, 2001. Lynx does not undertake any
obligation to update forward-looking statements.

This news release is not an offer to sell, or a solicitation of an offer to buy, the securities discussed herein. These
securities have not been registered under the Securities Act of 1933, as amended, and may not be offered and
sold in the United States unless registered under such act or an exemption from registration is available.

Lynx Therapeutics, Inc.

tb 2

Beitrag zu dieser Diskussion schreiben

Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.